Navigation Links
Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Date:10/23/2007

lopment of its key assets to build stockholder value. http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercializ
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
3. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
4. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
5. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
6. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
7. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... 30, 2015 First Choice Wellness Care recently ... Duality and is the only clinic in the greater ... removal treatments. The practice has recently expanded their services ... to showcase their focus in the procedure. They upgraded ... faster ink clearance, and superior service. "We,ve ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:6/30/2015)... , ... June 30, 2015 , ... Experts estimate that ... in life. Back pain can range from a dull, constant ache (chronic) to a ... as epidural steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Combat Soldiers face in the aftermath of a near-death experience (NDE) – and ... experiences and providing adequate treatment options – are invited to visit ...
(Date:6/30/2015)... ... 2015 , ... When it comes to volunteering abroad, not many people end ... be too high. However, there are affordable programs to be had such as those ... cost. One such volunteer named Uzma Aishah, a student at the International Medical University ...
(Date:6/30/2015)... ... June 30, 2015 , ... AvePoint, the established leader ... three new apps – AvePoint Watermark, AvePoint MyWorld, and ... these apps, workers can better streamline everyday business operations and take advantage of the ...
(Date:6/30/2015)... ... June 30, 2015 , ... Lecrae is quickly developing into one ... Rolling Stone and The New York Times to Billboard Magazine and Variety, among others. ... of the many reasons why so many people are taking notice. , “We are ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 3Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 2Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 2Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 3
... its employees further strengthen community support by donating an ... giving campaign DUBLIN, Ohio, Feb. 18 The Cardinal ... $1.2 million to non-profit programs that seek to improve ... Cardinal Health has the highest concentration of employees. Over ...
... (Nasdaq: ALGN ) today announced that the Company ... against the Company on February 17, 2009 by ClearCorrect, Inc. ... of Texas. Align Technology became aware of the filing on ... copy of the Complaint.In the Complaint, assigned case # H-09-470 ...
... Who Use the OmniPod System to Manage their Diabetes , ... country,s top professional cross-country skiers, is competing on behalf of ... As a world-class athlete, Freeman intends to medal, but he ... Diabetes doesn,t keep Freeman from performing at the top ...
... from this trial supported entry into Company,s current ... -,BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - Bioniche Life ... biopharmaceutical company, today announced that The Journal of ... II clinical trial results for the Company,s proprietary ...
... Calif., Feb. 18 In a dramatic move ... direct care RN organizations, the,United American Nurses, California ... Association today announced,they are joining together to form ... The new organization will be called the ...
... of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box solution for resellers ... ... -- SherWeb , a global leader in hosted solutions ... last week. The newly implemented program provides IT solution providers with ...
Cached Medicine News:Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 2Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 3Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 4Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 5Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Elite Skier Uses OmniPod(R) Insulin Management System at World Championships 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2
... D-Type can combine a number of ... microplates on a simple to use ... is a multifunctional stand-alone device but ... robotic systems. Custom and standard add-on ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
Medicine Products: